Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1

Studies using genetically modified mice have revealed fundamental functions of the transcription factor Fos/AP-1 in bone biology, inflammation, and cancer. However, the biological role of the Fos-related protein Fra-2 is not well defined in vivo. Here we report an unexpected profibrogenic function of Fra-2 in transgenic mice, in which ectopic expression of Fra-2 in various organs resulted in generalized fibrosis with predominant manifestation in the lung. The pulmonary phenotype was characterized by vascular remodeling and obliteration of pulmonary arteries, which coincided with expression of osteopontin, an AP-1 target gene involved in vascular remodeling and fibrogenesis. These alterations were followed by inflammation; release of profibrogenic factors, such as IL-4, insulin-like growth factor 1, and CXCL5; progressive fibrosis; and premature mortality. Genetic experiments and bone marrow reconstitutions suggested that fibrosis developed independently of B and T cells and was not mediated by autoimmunity despite the marked inflammation observed in transgenic lungs. Importantly, strong expression of Fra-2 was also observed in human samples of idiopathic and autoimmune-mediated pulmonary fibrosis. These findings indicate that Fra-2 expression is sufficient to cause pulmonary fibrosis in mice, possibly by linking vascular remodeling and fibrogenesis, and suggest that Fra-2 has to be considered a contributing pathogenic factor of pulmonary fibrosis in humans.

[1]  G. Hunninghake,et al.  Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis? A perspective. , 2007, Proceedings of the American Thoracic Society.

[2]  E. Wagner,et al.  Simultaneous generation of fra‐2 conditional and fra‐2 knock‐out mice , 2007, Genesis.

[3]  Giulio Gabbiani,et al.  The myofibroblast: one function, multiple origins. , 2007, The American journal of pathology.

[4]  S. Nathan,et al.  Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. , 2007, American journal of respiratory and critical care medicine.

[5]  M. Mishima,et al.  Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. , 2007, Chest.

[6]  R. Strieter,et al.  The role of CXC chemokines in pulmonary fibrosis. , 2007, The Journal of clinical investigation.

[7]  David Abraham,et al.  Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.

[8]  D. Sheppard,et al.  Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix , 2006, Proceedings of the National Academy of Sciences.

[9]  C. Agostini,et al.  Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. , 2006, Proceedings of the American Thoracic Society.

[10]  E. Wagner,et al.  Fos/AP‐1 proteins in bone and the immune system , 2005, Immunological reviews.

[11]  Naftali Kaminski,et al.  Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis , 2005, PLoS medicine.

[12]  C. Carvalho,et al.  Heterogeneous Remodeling of Lung Vessels in Idiopathic Pulmonary Fibrosis , 2005, Lung.

[13]  Daisuke Ogawa,et al.  Liver X Receptor Agonists Inhibit Cytokine-Induced Osteopontin Expression in Macrophages Through Interference With Activator Protein-1 Signaling Pathways , 2005, Circulation research.

[14]  J. Milbrandt,et al.  Early Growth Response Gene 1–mediated Apoptosis Is Essential for Transforming Growth Factor β1–induced Pulmonary Fibrosis , 2004, The Journal of experimental medicine.

[15]  M. Burdick,et al.  Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. , 2004, The Journal of clinical investigation.

[16]  L. Liaw,et al.  Altered bleomycin-induced lung fibrosis in osteopontin-deficient mice. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[17]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.

[18]  M. Olive,et al.  AP-1 Is Involved in UTP-Induced Osteopontin Expression in Arterial Smooth Muscle Cells , 2003, Circulation research.

[19]  S. Phan,et al.  Dual Roles of IL-4 in Lung Injury and Fibrosis1 , 2003, The Journal of Immunology.

[20]  A. Loewy,et al.  Osteopontin Transcription in Aortic Vascular Smooth Muscle Cells Is Controlled by Glucose-regulated Upstream Stimulatory Factor and Activator Protein-1 Activities* , 2002, The Journal of Biological Chemistry.

[21]  F. Ohsuzu,et al.  Osteopontin Plays an Important Role in the Development of Medial Thickening and Neointimal Formation , 2002, Circulation research.

[22]  Y. Kaneda,et al.  Inhibitory Effects of Novel AP-1 Decoy Oligodeoxynucleotides on Vascular Smooth Muscle Cell Proliferation In Vitro and Neointimal Formation In Vivo , 2002, Circulation research.

[23]  A. Nicholson,et al.  Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. , 2002, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[24]  S. Phan,et al.  Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis. , 2001, Cytokine.

[25]  E. Wagner,et al.  AP-1 in mouse development and tumorigenesis , 2001, Oncogene.

[26]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.

[27]  E. Wagner,et al.  Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1 , 2000, Nature Medicine.

[28]  M. Kelz,et al.  Overexpression of ΔFosB transcription factor(s) increases bone formation and inhibits adipogenesis , 2000, Nature Medicine.

[29]  S. Uh,et al.  Morphometric analysis of insulin-like growth factor-I localization in lung tissues of patients with idiopathic pulmonary fibrosis. , 1998, American journal of respiratory and critical care medicine.

[30]  D. Cohen,et al.  Overexpression of fra-2 in transgenic mice perturbs normal eye development , 1998, Oncogene.

[31]  J. Myers,et al.  Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. , 1998, American journal of respiratory and critical care medicine.

[32]  A. Rothman,et al.  Immediate-early gene expression in response to hypertrophic and proliferative stimuli in pulmonary arterial smooth muscle cells. , 1994, The Journal of biological chemistry.

[33]  E. Wagner,et al.  Osteoblasts are target cells for transformation in c-fos transgenic mice , 1993, The Journal of cell biology.

[34]  R. Puri,et al.  IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. , 2006, Nature medicine.